Global Markets

Resilience launches with $800m to ‘break’ biomanufacturing bottlenecks

Though details are scarce, Resilience claims it will provide ‘new, better, faster ways’ to manufacture cell and gene therapies. The new entity begins with bases in Boston and San Diego, as well as over 750,000-square-feet of operating space. Officially known as ‘National Resilience’, the company announced its entrance on the market by suggesting that it would be a ‘first-in-kind’ biomanufacturing and technology operation that has been set up specifically to address capacity issues in the advanced therapeutics area. Resilience plans…

SaudiVax works with Cytiva to produce halal vaccines

Cytiva provides its FlexFactory solution, as SaudiVax looks to meet vaccines and biologics demand in the Middle East and Africa. The FlexFactory platform is being installed as part of Saudi Arabia’s Saudi Vaccine and Bioprocessing Center (SVBC), which will become the first bioprocessing facility for halal vaccines in the region. It also represents new ground for Cytiva, with the FlexFactory installation being the first for the company in the Middle East and North African (MENA) region. The SVBC is backed…

Pfizer looks to freezer farms and thermal shippers to make COVID vaccine distribution ‘doable’

Pfizer says it is prepped to overcome the logistical challenges of distributing its mRNA vaccine against COVID-19 as it submits an Emergency Use Authorization (EUA) to the US FDA. Today, Pfizer submitted a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of BNT162b2, an mRNA vaccine candidate codeveloped with Germany’s BioNTech, against SARS-CoV-2. The news follows Phase III trial data showing the vaccine has an efficacy rate of 95% and marks a major milestone…

Celltrion commits $453m for third plant with 60,000 L capacity

Celltrion is constructing a third manufacturing plant at its site in Songdo, Korea and has a fourth in the works as it aims to have 600,000 L of bioreactor capacity operational by 2030. Korean drugmaker Celltrion has four biosimilars on the market and a pipeline consisting of five other potential biosimilar products and two novel biotherapeutics. Currently the firm has 190,000 L of bioreactor capacity available to it across two biomanufacturing facilities at its site in Songdo, Incheon, but aims…

Lonza making 400m doses of COVID vaccine and can scale up further if Moderna asks

With four manufacturing lines prepped to produce 400 million doses, Lonza has congratulated Moderna on positive interim results for its mRNA vaccine against COVID-19. Biopharma has appeared to gain the upper hand on its battle against COVID-19 in the past week. First Pfizer and BioNTech reported positive interim results – a 90% efficacy rate – in a Phase III study of its mRNA vaccine candidate, and days later Moderna topped this reporting that its mRNA vaccine was shown to be…

Hiring staff ‘extra challenging’ during pandemic, says Emergent VP

Emergent tries to fill bioprocessing talent gaps as it works to meet COVID-19 manufacturing demand. When the pandemic hit earlier this year, Emergent Biosolutions found its services as a specialist in vaccine development and manufacturing sought after by a number of leading efforts against COVID-19. The company’s contract development and manufacturing organization (CDMO) business unit found itself well placed, having already built up its capacity specifically to counter a pandemic alongside the US government. Alongside its newly found popularity as…

Flew vaccine? Merck teams to deliver meds by drone

Merck & Co. has partnered with Volansi to test delivering cold chain products from a North Carolina manufacturing facility to a nearby health clinic. The ‘pilot’ scheme sees Merck (known as MSD outside of North America) use Volansi’s VOLY C10 drone to deliver vaccines and medicinal products from its facility in Wilson, North Carolina to Vidant Healthplex-Wilson, a Vidant Health clinic about two miles away. “This project is starting with Merck’s vaccines against measles, mumps, rubella, chickenpox, pneumonia, and hepatitis,”…

Blockchain platform offers advanced therapy tracking ‘vein-to-vein’

Hataali blockchain technology used to secure supply chain in the UK could lead to a ‘standardized infrastructure’ for cell and gene therapy tracking, says ATMPS. ATMPS, a spin out from Farmatrust and the creator of the Hataali platform, tested the blockchain solution alongside the UK’s University Hospitals Birmingham NHS Foundation Trust (UHB). UHB is home to the Midlands and Wales Advanced Therapy Treatment Centre, which is comprised of partners from the NHS, academia and industry. The center, one of three…

Podcast: The impact of COVID-19 on the pharma and bio supply chain

Bioprocess Insider editor Dan Stanton joins an industry panel to discuss supply chain concerns stemming from the ongoing coronavirus crisis. Listen to the podcast now. Brought to you by international pharmaceutical content, digital and design agency ramarketing, the Molecule to Market podcast takes a listen to the contract outsourcing space with industry insights direct from the brains of the people that make the headlines. In this special episode, one of the headline writers – Bioprocess Insider founder and editor Dan…

Thermo Fisher: ‘$700m COVID CapEx easily repurposed post-pandemic’

An additional $700 million capacity buildout to meet COVID-related demand will serve the longer-term non-pandemic-related biopharma market, says Thermo Fisher An unprecedented third quarter saw Thermo Fisher report a 36% rise in revenues year-on-year to $8.52 billion across all its segments. Its Life Sciences Solutions Segment – which includes its biosciences and bioproduction business units – saw a 101% rise to $3.42 billion, while its Laboratory Products and Services Segment – which includes drug manufacturing – increased by 19% to…